• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
HealthMylan

Why a Democratic Senator Is Supporting Mylan’s CEO

By
Sy Mukherjee
Down Arrow Button Icon
By
Sy Mukherjee
Down Arrow Button Icon
September 7, 2016, 5:55 PM ET
President Obama Delivers State Of The Union Address
WASHINGTON, DC - JANUARY 20: House Minority Leader Nancy Pelosi (R) (D-CA) talks with Sen. Joe Manchin (L) (D-WV) before the start of the State of the Union speech in the House chamber of the U.S. Capitol January 20, 2015 in Washington, DC. U.S. President Barack Obama was expected to lay out a broad agenda including attempts to address income inequality and making it easier for Americans to afford college education and child care. (Photo by Rob Carr/Getty Images)Photograph by Rob Carr—via Getty Images

Mylan (MYL) CEO Heather Bresch isn’t the most popular among the public and lawmakers right now. But at least one elected official is singing her praises: her father, Senator Joe Manchin (D-W.Va.).

Bresch and her pharma company have been staring down a deluge of criticism for hiking the price of the EpiPen, a device used to fight potentially lethal allergic reactions, by more than 400% over the last decade. Members of Congress have called for a formal investigation, while New York attorney general Eric Schneiderman announced Tuesday that he’d launched an antitrust probe into Mylan for potentially putting anti-competitive language into its contracts with local school districts.

Manchin, however, defended his daughter in an interview with Bloomberg on Tuesday evening.

Click here to subscribe to our new Brainstorm Health Daily Newsletter.

“My daughter is my daughter with unconditional love and she’s the most amazing person that I know of as far as not only being accomplished, but just, she’s so compassionate and generous in how she’s always lived her life,” he said.

Manchin went on to say that his daughter would make sure anyone who informed Mylan they couldn’t afford an EpiPen would undoubtedly receive one. “[S]he would give them one,” he said. “That’s all. I know that. I know her well enough to know that would happen.”

Mylan has significantly boosted its coupons for patients since the firestorm over the EpiPen and plans to introduce a generic competitor to its own product at half the price.

 

Manchin acknowledge that he knew little about Mylan’s individual business practices and called drug pricing a “convoluted” issue. But he assured that his daughter would answer any of his colleagues’ questions about pricing and hoped that Bresch would receive a fair shake.

By shining light on high drug prices and price hikes, which are common throughout the biopharma industry, Manchin said all the attention the EpiPen’s tab could be a “blessing in disguise.”

“They are all too expensive,” he said. “So if there is a way to find out that we can deliver it at a better, more economical price, and still have the innovative and creative juices flowing I guess that makes all these things happen, you’ve got to find the balance somewhere.”

About the Author
By Sy Mukherjee
See full bioRight Arrow Button Icon

Latest in Health

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

Latest in Health

SuccessMillionaires
Tech CEO Bryan Johnson says he’ll make humans immortal by 2039—first he just needs to sort out ‘buggy’ issues like ‘mistakenly causing cancer’
By Orianna Rosa RoyleDecember 17, 2025
24 hours ago
Johnson
PoliticsHealth Insurance
Vulnerable Republican blasts choice to send health insurance spiking as ‘political malpractice’
By Kevin Freking, Lisa Mascaro and The Associated PressDecember 16, 2025
1 day ago
FDA
HealthDrugs
Female libido pill gets expanded approval for menopause by FDA
By Matthew Perrone and The Associated PressDecember 15, 2025
3 days ago
HealthCommentary
Nicotine pouches offer huge promise—so long as the U.S. doesn’t repeat its mistake with vaping
By Max CunninghamDecember 14, 2025
4 days ago
Thompson
C-SuiteMedia
Atlantic CEO Nick Thompson on how he learned to ‘just keep moving forward’ after his famous firing at 22
By Nick LichtenbergDecember 14, 2025
4 days ago
HealthAffordable Care Act (ACA)
A Wisconsin couple was paying $2 a month for an ACA health plan. But as subsidies expire, it’s soaring to $1,600, forcing them to downgrade
By Ali Swenson and The Associated PressDecember 13, 2025
5 days ago

Most Popular

placeholder alt text
Economy
The $38 trillion national debt is to blame for over $1 trillion in annual interest payments from here on out, CRFB says
By Nick LichtenbergDecember 17, 2025
19 hours ago
placeholder alt text
Success
As millions of Gen Zers face unemployment, McDonald's CEO dishes out some tough love career advice for navigating the market: ‘You've got to make things happen for yourself’
By Preston ForeDecember 16, 2025
2 days ago
placeholder alt text
Economy
America's $38 trillion national debt 'exacerbates generational imbalances' with Gen Z and millennials paying the price, warns think tank
By Eleanor PringleDecember 16, 2025
2 days ago
placeholder alt text
AI
'Robots are going to be amongst us': Qualcomm exec says buckle up for the next 5 years. Your car is going to be the first shoe to drop
By Nino PaoliDecember 17, 2025
1 day ago
placeholder alt text
Innovation
An MIT roboticist who cofounded bankrupt Roomba maker iRobot says Elon Musk's vision of humanoid robot assistants is 'pure fantasy thinking'
By Marco Quiroz-GutierrezDecember 16, 2025
2 days ago
placeholder alt text
AI
IBM, AWS veteran says 90% of your employees are stuck in first gear with AI, just asking it to ‘write their mean email in a slightly more polite way’
By Marco Quiroz-GutierrezDecember 16, 2025
2 days ago

© 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.